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Abstract
Nucleotides and nucleosides influence nearly every aspect of physiology and pathophysiology. Extracellular nucleotides
are metabolized through regulated phosphohydrolysis by a series of ecto-nucleotidases. The formation of extracellular
adenosine from adenosine 50-monophosphate is accomplished primarily through ecto-50-nucleotidase (CD73), a glycosyl
phosphatidylinositol-linked membrane protein found on the surface of a variety of cell types. Recent in vivo studies
implicating CD73 in a number of tissue protective mechanisms have provided new insight into its regulation and function
and have generated considerable interest. Here, we review contributions of CD73 to cell and tissue stress responses, with
a particular emphasis on physiologic responses to regulated CD73 expression and function, as well as new findings
utilizing Cd73-deficient animals.
Introduction
Circulating or locally released nucleotides are rapidly
metabolized by ecto-enzymes localized on the cell surface.
Ecto-50-nucleotidase (CD73) is a glycosyl phosphatidylino-
sitol (GPI)-linked, membrane-bound glycoprotein which
hydrolyzes extracellular nucleoside monophosphates into
bioactivenucleosideintermediates[1]. Surface-bound CD73
metabolizes adenosine 50-monophosphate (AMP) to aden-
osine, which when released can activate one of four types
of G-protein coupled, seven transmembrane spanning
adenosine receptors (AdoR) or can be internalized through
dipyridamole-sensitive carriers [2]. Adenosine receptors
are expressed on a wide variety of cells, and many cell
types have been shown to express more than one isoform
of the receptor. Likewise, activation of surface AdoR has
been shown to regulate diverse physiologic endpoints. In
the recent years, our understanding of nucleotide metabolic
pathways has benefited from the development of geneti-
cally manipulated animals, particularly mice deficient in
Cd73 or a second nucleotide metabolizing enzyme, Cd39
(ecto-apyrase), that catalyzes the phosphohydrolysis of
ATP and ADP to AMP. Here, we build on outstanding
previous reviews [1, 3] to provide concise summation of
relevant studies addressing physiologic influences of
CD73 in multiple settings and utilizing a variety of model
systems.
Physiological responses coordinated by CD73
Epithelial ion and fluid transport
A primary physiologic function of epithelial cells is water
transport. Mucosal tissues lined by epithelia, such as the
lung and intestine, accomplish this function through a
coordinated series of ion transport events [4]. As part of a
tissue adaptive response, a number of purine nucleotide
metabolites, including adenosine, have been shown to
influence epithelial electrogenic chloride secretion, the
transport event responsible for mucosal hydration [4]. This
aspect of epithelial function has been studied in detail
utilizing models of intact epithelial cell layers coupled with
electrophysiologic strategies. Original studies by Madara
et al. examining biological properties of soluble mediators
derived from activated inflammatory cells (e.g. neutrophils
and eosinophils) identified a small, protease-resistant
fraction termed neutrophil-derived secretagogue (NDS),
which when incubated on epithelia, activated electrogenic
chloride secretion and fluid transport. Subsequent biophys-
ical analysis of NDS identified this molecule to be AMP [5].
With no known AMP receptor, studies turned toward
defining potential metabolic pathways for adenosine
generation. Biochemical and pharmacologic studies dem-
onstrated the polarized expression of CD73 on the apical
Correspondence to: Sean P. Colgan, CenterforExperimentalTherapeutics,
Brighamand Women’sHospital, Harvard Medical School, Thorn Building
704, 75 Francis Street, Boston, Massachusetts 02115, USA. Tel: +1-617-
2780599; Fax: +1-617-2786957; E-mail: colgan@zeus.bwh.harvard.edu
Purinergic Signalling (2006) 2: 351–360 # Springer 2006
DOI: 10.1007/s11302-005-5302-5surface of cultured and primary intestinal epithelial cells
[6]. Further biochemical and morphological studies
revealed that CD73 exists in both a GPI-linked surface
fraction as well as in a sub-apical caveolin-rich domain
within the epithelium. Such expression patterns have
subsequently been shown in a variety of mucosal epithelial
cell types.
At present, it is not known how CD73 directly influences
ion transport properties of intact tissues. Of note on this
accord, tissues with high ion transport capacities appear to
express high levels of CD73. For example, as part of one
study addressing the phenotype of Cd73
j/j mice [7] (also
see later), quantification of CD73 enzyme activity (i.e.,
AMP hydrolyzing activity inhibited by a,b-methylene-
ADP, APCP) in a range of tissues produced several
important findings. First, there was a nearly 50-fold
variation in CD73 ecto-50-nucleotidase enzyme activity in
different tissues from wild-type animals. Second, of the
tissues surveyed, colon showed the highest level of enzyme
activity, a somewhat surprising result, as a number of
previous studies suggested that the kidney likely carried
the highest activity of any tissue. Instead, it was found that
the colon expresses nearly twice as much activity as the
kidney, with the rank order of tissue activity as follows:
Colon > kidney = brain 9 liver 9 lung 9 heart 99 muscle.
Furthermore, AMP hydrolyzing enzyme activity that was
not attributed to CD73 (i.e., nucleotidase and/or phospha-
tase activity that was not inhibited by APCP) also varied up
to 20-fold between individual tissues. Why such seemingly
disparate enzyme expression patterns exist is not clear at
present. However, the data suggest tissue-specific patterns
of extracellular nucleotide metabolism and differences in
the relative contribution of CD73 to extracellular adenosine
generation among individual tissues, including those
important in ion transport. Taken together, these studies
implicate CD73 as a metabolic control point for the
activation of adenosine-mediated fluid transport that likely
represents a primitive Fflushing_ mechanism across the
luminal aspect of the mucosa.
Barrier function
A number of studies have implicated CD73 in the control
of tissue barrier function. Successful transmigration of
leukocytes, particularly polymorphonuclear (PMN, neutro-
phil) leukocytes across the vascular endothelium is accom-
plished by temporary self-deformation with localized
widening of the inter-junctional spaces [8, 9], a process
with the potential to disturb endothelial and epithelial
barrier function. Original studies by Lennon et al. revealed
that the prominent signaling pathway for closing inter-
endothelial gaps during neutrophil transmigration involved
adenosine-stimulated Fresealing_ of the barrier [10].
Until recently, only limited information existed regard-
ing the biochemical events which regulate cellular barriers
in the setting of either neutrophil activation or transmigra-
tion [8, 9]. In the course of the aforementioned studies by
Lennon et al. examining interactions of leukocytes at
cellYcell junctions, it was revealed that inhibition of
CD73 using either APCP or anti-CD73 monoclonal
antibody 1E9 inhibited the resealing of endothelial and
epithelial barriers by as much as 85% [10], suggesting the
necessity for extracellular nucleotide metabolism in this
pathway. Subsequent studies revealed that adenosine
produced from neutrophil-derived AMP was responsible
for enhanced barrier function via activation of the
adenosine A2B receptor coupling to cytoskeletal links
[11]. More recently, it was shown that in addition to (or
rather than) releasing AMP, neutrophils actively release
ATP following receptor-mediated stimulation [12]. Such
ATP is hydrolyzed to adenosine at the endothelial cell
surface through the coordinated actions of CD39 and CD73
[13]. From this perspective, some evidence exists that ecto-
nucleotidases and ecto-ATPases can exist as a soluble,
circulating enzymes. Yegutkin et al., for example, demon-
strated that endothelial shear stress induces the release of
surface protein capable of ATP and AMP phosphohydro-
lysis [14]. The source of this activity was the cell surface,
and presumably represents soluble forms of CD73 and
CD39. Likewise, this same study revealed that shear stress
induces the release of endogenous ATP. It is clear exactly
how neutrophils and/or endothelial cells release ATP,
although several mechanisms have been proposed, includ-
ing direct transport through ATP-binding cassette (ABC)
proteins, transport through connexin hemichannels, as well
as vesicular release [15].
Important in this regard, there may be some specificity
to the regulation of barrier function by individual leukocyte
populations. For example, Henttinen, et al.showed that
adherent lymphocytes rapidly deaminate adenosine at the
vascular interface, effectively decreasing adenosine con-
centrations [16]. Under such conditions, lymphocytes were
shown to impair endothelial barrier function. It is possible,
for example, that these differences between neutrophils and
lymphocytes are explained by the relative expression
patterns of adenosine deaminase, particularly given the
prominent expression of lymphocyte adenosine deaminase
[17].
Clearly, CD73 lies central to the regulation of tissue
barriers. As an example, studies in mouse models of
intestinal permeability revealed that oral delivery the CD73
inhibitor APCP increases movement of inert tracers, such
as FITC-labelled dextran, across the intestinal epithelium
[18]. To investigate changes in vascular permeability in
Cd73
j/j mice [7] (see discussion later), we have used
Evan’s blue dye, which binds tightly to plasma albumin
[19]. Quantification of formamide-extractable Evan’s blue
from individual tissues can then be interpreted as a function
of vascular leak [20]. In general, hypoxia increases vascular
permeability two- to four-fold over normoxic conditions,
depending on the tissue being studied [13]. Pharmacologic
interventions have suggested that CD73 is protective under
such circumstances, and most studies have suggested a
protective role for adenosine A2 receptors in maintaining
barrier function [21]. Taken together, these studies define
CD73 as a gatekeeper for the fine tuning of epithelial and
endothelial permeability. Such innate protective pathways
share the common strategy of increasing extracellular ade-
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at the cell surface.
Adaptation to hypoxia
Generation of extracellular adenosine has been widely
implicated as an adaptive response to hypoxia. Studies
dating back more than 20 years indicated that tissue and
plasma adenosine levels increase during hypoxic stress
[22, 23]. For example, in human volunteers subjected to
ambient hypoxia (SpO2 = 80% over 20 min), plasma
adenosine concentrations increased from 21 to 51 nM in
the presence of dipyridamole, an inhibitor of adenosine
reuptake [24]. Similarly, when measuring adenine nucleo-
tide concentrations in neurally and vascularly isolated,
perfused skeletal muscles of anesthetized dogs, normobaric
hypoxia was associated with increases of adenosine in the
venous blood, but not of AMP, ADP or ATP [25]. A
possible role for adenosine during hypoxia may include
vasodilation. For instance, it has been suggested that
elevations in intracellular nitric oxide as a result of
adenosine A1 receptor activation may be responsible for
the vasodilatory properties of adenosine [26, 27]. Thus,
increases in adenosine tissue concentrations during hypoxia
may promote blood flow to hypoxic tissues, thereby
providing an innate protective response to hypoxia. Rather
little is known about the regulation of CD73, and whether
regulated expression provides a physiologic role. A number
of studies have suggested that CD73 contributes to the
protective aspects of adenine nucleotide metabolism during
hypoxia and ischemia (see later).
Molecular mechanisms leading to elevations of adeno-
sine in hypoxia are only now being elucidated. The cloned
Cd73 gene promoter contains a cAMP response element
(CRE) [28], a consensus DNA motif which regulates
transcription through the cAMP-dependent co-activator
CRE-binding protein (CREB) [29]. Activation of either
the adenosine A2A or A2B receptor elevates intracellular
cAMP and CREB2, providing the possibility that the
enzymatic product of CD73 (adenosine) transcriptionally
regulatessurfaceenzyme(CD73)expression.Morerecently,
hypoxiahasbeen showntoupregulateCD73expressionand
function in several different cell types [13, 18, 30Y32]. As
part of these studies, we observed a rapid and prolonged
induction of CD73 in epithelia [18]. Given the long lasting
and robust hypoxia response observed, a candidate regula-
tor was hypoxia-inducible factor-1 (HIF-1). As a global
regulator of oxygen homeostasis, the ab heterodimeric
transcription factor HIF-1 facilitates both oxygen delivery
and adaptation to oxygen deprivation [33]. HIF-1 is a
member of the Per-ARNT-Sim (PAS) family of basic
helix-loop-helix (bHLH) transcription factors. HIF-1 acti-
vation requires stabilization of an O2-dependent degrada-
tion domain (ODD) in the a subunit and subsequent
nuclear translocation to form a functional complex with
HIF-1b and cofactors such as CBP and its ortholog p300
[34]. Under conditions of adequate oxygen supply, iron-
and oxygen-dependent hydroxylation of two prolines
(Pro
564 and Pro
402) within the ODD of HIF-1a initiates
the association with the von HippelYLindau tumor sup-
pressor protein (pVHL) and rapid degradation via ubiq-
uitin-E3 ligase proteasomal targeting [35, 36]. A second
hypoxic switch operates in the carboxy terminal trans-
activation domain of HIF-1a. Here, hypoxia blocks the
hydroxylation of Asp
803, thereby facilitating the recruit-
ment of CBP/p300 [37].
A search of the cloned Cd73 gene promoter revealed a
classic HIF-1 binding DNA consensus motif 50-CCGTG-30
located at positions j367 to j371 relative to the major
transcription start site [18]. However, the existence of a
HIF-1 binding consensus site is not evidence for a HIF-1-
mediated response. A classic HIF-1 response element
(HRE) is defined as a cis-acting transcriptional regulatory
sequence located within 50-flanking, 30-flanking or inter-
vening sequences of target genes. Three approaches were
used to define a role for HIF-1 in the induction of CD73
expression. First, HIF-1a antisense oligonucleotides sig-
nificantly reduced the induction of CD73 under hypoxic
conditions in bovine aortic endothelial cells transiently
transfected with a Cd73 promoter luciferase reporter
construct. Second, truncated reporter constructs identified
a functional hypoxia responsive element located between
j518 and j92 nucleotides upstream of the major
transcription start site of the Cd73 gene. Finally, a two
nucleotide mutation in a consensus HIF-1a binding site in
the Cd73 promoter led to a complete loss of hypoxia
inducibility of the luciferase reporter construct. These
studies also implicated transcriptional repressor elements
for CD73 expression in hypoxia. For example, some of the
larger truncated promoter constructs showed increased
hypoxia-inducibility than the full length promoter, suggest-
ing the presence of at least partial repressor activity [18]. A
number of consensus binding sites map to this region of the
promoter, and while we have not directly addressed this
issue, at least two transcription factors (GATA-1 and
GATA-2) have recently been implicated in gene repression
in hypoxia. Thus, it is probable that both positive and
negative regulatory pathways contribute to molecular
regulation Cd73 promoter activity.
Ischemic preconditioning
Cells of the cardiovascular system generate and release
adenosine in increasing quantities during stress or when
subjected to injurious stimuli. This increased adenosine can
interact with surface receptors in myocardial, vascular,
fibroblast, and inflammatory cells to modulate cellular
function and phenotype [13]. Via these receptor-dependent
and independent (metabolic) pathways, adenosine can
substantially modify the acute response to ischemic insult,
in addition to generating a more sustained ischemia-
tolerant phenotype (preconditioning). However, the molec-
ular basis for acute adenosinergic cardioprotection remains
poorly understood [38].
The potential for adenosine to exert cardioprotective
influences on the ischemic myocardium is well-documented
[38]. While the source of interstitial adenosine in hypoxic
tissue has been the basis of much debate, it is generally
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represents the major pathway of extracellular adenosine
formation during oxygen supply imbalances [2]. Extracel-
lular adenosine production in the ischemic myocardium,
for example, is attributable to activity of CD73 [39], and
both CD73 activity and adenosine metabolism have been
demonstrated in cardiac pre-conditioning by brief periods
of ischemia [40, 41]. Increased CD73 activity in ischemic
preconditioning (IP) has been attributed to a variety of
acute activation pathways [42], and as alluded to above,
CD73 is transcriptionally regulated by HIF-118. Because
ecto-50-nucleotidase (CD73) is induced during ischemia
and hypoxia [13], it is thought to be primarily responsible
for adenosine production under those circumstances.
Some evidence indicates that the increase in CD73 in
myocardium subjected to IP may originate from myocytes,
but the immediate influence of myocytes on CD73 activity
is not well understood [38]. The relative importance of
CD73 in cardiac tissue was recently demonstrated using
Cd73
j/j mice [43]. In the isolated perfused heart, it was
shown that AMP hydrolyzing activity attributable to CD73
accounted for 60% of the total hydrolytic activity during a
single passage through the coronary vasculature. Further-
more, histochemical analysis revealed CD73 to be the
predominant AMPase associated with the vascular endo-
thelium of large conduit vessels such as the aorta, carotid,
and coronary artery with no measurable contribution by
alkaline phosphatase [43].
Activation of adenosine A1 and possibly A3 receptors is
believed to protect heart and other tissues by precondition-
ing through a pathway including protein kinase C and
mitochondrial KATP channels. Activation of adenosine A2A
receptors seems to limit reperfusion injury by inhibiting
inflammatory processes in neutrophils, platelets, macro-
phages and T cells [2]. The role of the adenosine A2B
receptor in IP is unknown, although some evidence
suggests that it may be involved in the inhibition of
cardiac fibroblast proliferation, protein, and collagen
synthesis [44]. It is worth noting here that much of the
controversy regarding receptor identities stems from the
major problem that many receptor agonists and antagonists
previously thought to be highly selective are in fact capable
of interacting with multiple receptor subtypes at concen-
trations typically employed [38].
CD73 and inflammation
For more than two decades, it has been appreciated that
adenosine attenuates potentially harmful aspects of neutro-
phil activation [45]. More recent studies have focused on
targeting adenosine receptors to limit tissue injury in a
variety of diseases using either native adenosine or
pharmacological agonism/antagonism with receptor-selec-
tive analogs [2, 46, 47]. Lessisknownabouttheinfluenceof
endogenously generated adenosine on neutrophil function.
Original work by Rosengren, et al. [48] using the non-
selective adenosine receptor antagonist 8-phenyl-theophyl-
line demonstrated enhanced inflammation in the hamster
cheek pouch, thereby suggesting tonic regulation of
neutrophil receptors to endogenous adenosine sources.
More recent studies using new reagents and new insight
into metabolic pathways to generate extracellular adeno-
sine (i.e., CD39 and CD73) provide an opportunity to
understand these pathways with more clarity.
In other examples, acute hypoxemia has been shown to
enhance neutrophil activation responses [49]. For instance,
Figure 1. Model of coordinated nucleotide metabolism and nucleoside signaling in hypoxia and inflammation. In areas of ongoing inflammation,
diminished oxygen supply coordinates the induction of CD39, CD73, and the adenosine A2B receptor. At such sites, activated neutrophils provide a
readily available extracellular source of ATP, that through two enzymatic steps is converted to extracellular adenosine. Activation of surface adenosine
receptors promotes a variety of protective physiologic responses (see text). Abbreviations: A, adenosine; AdoRA A2, adenosine receptor; AMP, adenosine
monophosphate; ATP, adenosine triphosphate; cAMP, cyclic AMP.
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the intravascular space to the interstitium, and such
responses may contribute significantly to tissue damage
during consequent reperfusion injury [50Y52]. Moreover,
emigration of PMN through the endothelium and epitheli-
um may lead to a disruption of tissue barriers [53] and
create the potential for extravascular fluid leakage and
subsequent edema [54, 55].
By contrast, transcriptional pathways mediated by HIF-1
may serve as barrier-protective elements during inflamma-
tory hypoxia. For example, experimental studies of murine
colitis have revealed extensive mucosal hypoxia and
concomitant HIF-1 activation [56]. Mice engineered to
conditionally delete intestinal epithelial HIF-1a exhibit
more severe clinical symptoms of colitis, while conditional
increases in epithelial HIF-1 are protective. Furthermore,
colons with constitutive activation of HIF-1 displayed
increased expression levels of HIF-1 regulated barrier-
protective genes (multidrug resistance gene-1, intestinal
trefoil factor, CD73), attenuating the loss of barrier
function during colitis in vivo. CD73 was particularly
interesting from this perspective. During active phases of
colitis, CD73 mRNA was increased õ4 fold in wild-type
animals. Parallel analyses in animals expressing consititu-
tively active HIF-1 revealed a nearly 18-fold increase in
CD73 mRNA [56]. Such findings confirm previous
observations of HIF-1 dependent regulation of CD73
expression, and define an inflammatory metabolic loop
involving a contribution of hypoxia, a condition we have
termed Finflammatory hypoxia_ [57].
The vascular endothelium is the primary interface
between tissue inflammatory signals and circulating leu-
kocytes [58]. As such, the endothelium is central to the
orchestration of leukocyte trafficking in response to
chemotactic stimuli. This critical anatomic location places
vascular endothelial cells in an ideal position to coordinate
extracellular metabolic events important to endogenous
anti-inflammatory responses. We have recently identified a
neutrophil-endothelial cell crosstalk pathway that is coor-
dinated by hypoxia (see Figure 1). This pathway utilizes
extracellular nucleotide substrates liberated from different
cell types. Extracellular ATP release has been shown from
endothelial cells, particularly under sheer conditions or in
hypoxia. In addition, neutrophils can release ATP in an
activation-dependent manner [12, 13]. Recent studies from
our lab indicate that neutrophils express CD39, and can
therefore also contribute to the extracellular metabolism of
ATP (manuscript in preparation).
Activated platelets comprise an additional source of
extracellular adenine nucleotides [59, 60]. The generation
of AMP from ATP/ADP by endothelial CD39 has been
viewed as a protective, thromboregulatory mechanism for
limiting the size of the hemostatic plug [60, 61]. Metab-
olism of adenine nucleotides derived from activated
platelets is crucial in limiting excessive platelet aggrega-
tion and thrombus formation [62, 63]. Similarly, excessive
platelet accumulation and recruitment can be treated with
soluble forms of CD39 [64, 65]. Moreover, a thrombo-
regulatory role was demonstrated in a model of stroke,
where Cd39-null mice showed increased infarction size
that was reduced by treatment with soluble CD39 [66].
Surprisingly, targeted disruption of Cd39 resulted in
prolonged bleeding and increased vascular leak and fibrin
deposition in hypoxemia [67], suggesting a dual role for
ATP metabolism by CD39 in modulating both hemostatic
and thrombotic reactions. This latter observation may be
related to an activation and desensitization of the puriner-
gic type P2Y1 receptor by ATP. Engagement of the P2Y1
platelet receptor appears to be crucial to the process of
platelet activation. As such, P2Y1-deficient mice exhibit
signs of prolonged bleeding time and resistance to throm-
boembolism [68]. In contrast to these studies, we observed
a barrier-protective influence of CD39 during hypoxia that
was not related to the activation of P2 receptors, but rather
to the downstream metabolism and signaling of ATP
metabolites (especially adenosine).
Extracellular ATP is readily converted to adenosine on
the endothelial surface, due to the sequential enzymatic
function of CD39 and CD73. Adenosine binds to surface
expressed adenosine receptors on PMN to limit excessive
accumulation of PMN within tissues, functioning as a
feedback loop to attenuate potential tissue injury [13]. With
regard to this latter point, it was recently shown that
hypoxia coordinates both transcriptional and metabolic
control of the surface ecto-nucleotidases CD39 and CD73
[13, 18, 32], and as such, significantly amplifies the
extracellular production of adenosine from adenine nucle-
otide precursors. In fact when using Cd39- and Cd73-null
animals, we found that extracellular adenosine produced
through adenine nucleotide metabolism during hypoxia is a
potent anti-inflammatory signal for PMN in vivo. These
findings identify CD39 and CD73 as critical control points
for endogenous adenosine generation and implicate this
pathway as an innate mechanism to attenuate excessive
tissue PMN accumulation [13].
HostYmicrobial interactions
It is recently been appreciated that CD73 may also
contribute in host responses to microbial infection. While
these studies are clearly in their infancy, this area is likely
to prove fruitful with further investigation. For example, it
is now appreciated that a symptomology associated with
some intestinal pathogens may be related to extracellular
metabolism of nucleotides. Indeed, Crane et al. showed
that damage related to epithelial infection by enterpatho-
genic E. coli liberates extracellular ATP, and via CD73-
dependent pathways generates adenosine [69]. As alluded
to above, adenosine is a potent secretagogue, and under
such circumstances, may promote symptoms of secretory
diarrhea in the intestine.
Likewise, some evidence suggests that CD73 may
contribute to microbial responses mediated by Toll-like
receptors (TLRs), although most studies have been indirect.
TLR signaling pathways are currently an area of intense
investigation, and while many cell types express machinery
for TLR-mediated signaling, the most thoroughly studied
have been those of monocytes/macrophages as well as
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lineages appear to express CD73, and it has been suggested
that such expression may regulate diverse functions ranging
from angiogenesis to B-cell maturation [70, 71]. Frantz
et al., have suggested that signaling through TLR and
adenosine (via stress activated CD73) may provide a con-
textual Finjury_ signal, and among other signaling path-
ways, may promote a strong angiogenic response [72]. In
strong agreement, work by Pinhal-Enfield et al. and
Leibovich et al. defined synergy between various TLR
agonists and adenosine receptors with regard to angiogen-
esis [73, 74]. Under these circumstances, agonists of TLR
2, 3, 4, 7 and 9 synergized with A2 receptors to induce
vascular endothelial growth factor and repress tumor ne-
crosisfactor.TheexactcontributionofCD73tothesemodels
is unclear, but better defining the source(s) of endogenous
adenosine should shed light on these interesting pathways.
CD73 may also contribute to responses following virus
infection. For example, Kas-Deelen et al. recently reported
that endothelial infection by cytomegalovirus (CMV)
increases expression and activity of both ecto-ATPase(s)
and CD73 [75]. These findings were based on studies
which indicated that CMV-infected endothelia have in-
creased turnover of 50-AMP, and that soluble mediators
derived from CMV-infected cultures attenuate neutrophil
activation responses. Systematic characterization of this
model identified the coordinated extracellular metabolism
of ATP and AMP to adenosine as the functional link.
While it is unclear how CMV enhances ecto-nucleotidase
activity and/or expression, it is possible that viral infection
could provide a feed-forward host response to promote
CD73 expression and activity. For example, Niemela has
shown that cytokines induced by virally infected cells (e.g.,
interferon-alpha) prominently induce CD73 expression and
adenosine production on the endothelium in vitro and
in vivo [76]. Such responses were, at least in part, cell-type
specific for endothelial cells, and were not observed in
lymphocytes. These findings provide important insight into
mechanisms of CD73 regulation, and further define the
importance of CD73 in innate immune responses.
Studies in Cd73-deficient mice
At least three separate groups have generated Cd73-
deficient mice within the course of a two-year span [7,
43, 77], each targeting one or more exons required for the
ecto-50-nucleotidase enzyme activity of CD73. Cd73-
deficient mice have no obvious phenotype when main-
tained in conventional housing. They breed normally and




pups are born to heterozygous parents in the expected 1:2:1
ratio. Below are some characteristics of physiologic re-
sponse observed in these animals.
Renal function
It has long been known that adenosine is an important
mediator in the kidney, primarily through regulation of
glomerular filtration. Tubuloglomerular feedback involves
a functional interplay between the tubular epithelium in the
environment of the macula densa and underlying arteriole
smooth muscle cells. As salt concentrations increase in the
luminal fluid surrounding the macula densa, smooth
muscle activation results in vasoconstriction of the arterio-
les. As a result, both the glomerular filtration pressure and
filtration rates decrease. To assess the contribution of
CD73-generated adenosine in local hemodynamic control
mechanisms in the kidney, Castrop et al. compared
tubuloglomerular feedback in the kidneys of Cd73
j/j and
wild type mice [77]. Interestingly, kidney function of
Cd73-deficienct mice was found to be normal with respect
to renal blood flow, renal vascular resistance, stimulation
of renin secretion by furosemide, plasma osmolarity, and
plasma concentrations of Na
+,C l
j, BUN, creatinine, uric
acid, and total protein. However, in response to saturating
increases in tubular perfusion flow, Cd73
j/j animals
demonstrated significantly decreased reductions in stop
flow pressure and superficial nephron glomerular filtration
rates compared to wild type animals. Furthermore, although
wild type mice showed relatively constant tubuloglomer-
ular feedback responses during prolonged perfusion of
the loop of Henle, the residual feedback response was
nearly lost in Cd73
j/j mice. Nevertheless, isolated
afferent arterioles from Cd73
j/j mice showed normal
contractile responses to exogenous adenosine, suggesting
that the observed deficiencies in tubuloglomerular feed-
back responses were due to decreased concentrations of
extracellular adenosine, rather than any defects in adeno-
sine receptor activation. In total, it was concluded that
CD73 serves as an important means of communication be-
tween the macula densa and the underlying smooth muscle
cells.
Hypoxia and vascular leak
Progress has been made in defining the role of CD73 in
hypoxia adaptation in vivo using Cd73-deficient mice [7].
These mice have provided some insight into adaptative
hypoxia responses, and strongly extend the previous
molecular studies of HIF-1a-dependent regulation of
CD73 expression. For example, as discussed above,
Thompson, et al. have recently shown that vascular leak
syndromes associated with hypoxia are significantly ac-
centuated in mice lacking CD737. In an attempt to define
the role of CD73 in vascular permeability, we used this
hypoxia model and compared wild-type and Cd73
j/j mice
administered either vehicle or the 50-nucleotidase inhibitor
APCP. These studies revealed a profound increase of
hypoxia-induced vascular leak in different organs (lung,
heart, intestine, kidneys) in response to CD73 inhibition or
genetic deficency. Pulmonary leak was particularly obvi-
ous in these mice. Indeed, lung vascular leak was highly
influenced by exogenous administration of APCP in wild-
type animals, and the vascular leak phenotype was most
prominent in the lungs of Cd73
j/j mice. Closer histolog-
ical examination revealed perivascular interstitial edema
with inflammatory infiltrates surrounding the larger con-
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j/j
animals subjected to hypoxia. Vascular leak was confirmed
by assessment of lung wet:dry ratios, with a nearly 70%
increase in lung water content of Cd73
j/j compared to
wild type mice.
These mice have also been useful in undersanding the
basic aspects of vascular permeability in intact organs. Our
studies have consistenty demonstrated that adenosine
promotes vascular barrier, and since elevation of cAMP is
associated with increased barrier function [78], it is likely
that our results represent activation of adenosine A2A and/
or A2B receptors. The A2B receptor may well be the target,
as A2B receptor mRNA is up regulated by hypoxia and A2B
receptor antagonists neutralize ATP-mediated changes in
post-hypoxic endothelial barrier function [13]. Additional-
ly, experiments with the adenosine receptor antagonists
MRS 1754 and ZM241385, suggest that both the A2A and
A2B receptors contribute to the changes in vascular barrier
during hypoxia [7]. An A2B receptor gene-targeted mouse
will be required to confirm this conclusion with certainty.
Alternatively, inosine could mediate these responses. We
think this is unlikely since inosine binds primarily to the A3
receptor [79] (a class of adenosine receptor that mediates
decreased cAMP), and it is likely that Cd73
j/j mice retain
the ability to generate inosine through the combined action
of AMP deaminase and cytoplasmic nucleotidases. The use
of animals with constitutive gene deletions provides a
global view of gene function, but fails to reveal how local
changes may impact a given response. Future studies using
animals with conditionally deleted Cd73 will likely provide
additional insight into these issues.
Platelet function
Nucleotides and nucleotide metabolism have been widely
implicated in platelet function [80, 81]. Cd73-deficient
animals have revealed some insight with regard to the role
of CD73-generated adenosine in platelet thrombosis in vivo
[43]. Initial studies of ADP-stimulated platelet aggregation
ex vivo have not revealed significant differences between
wild-type and Cd73-deficient animals, suggesting that
platelet function is intrinsically normal in Cd73 gene-
targeted mice. However, bleeding time after tail tip
resection and vessel occlusion induced by free radical
injury were significantly reduced in the Cd73-deficient
animals, suggesting a degree of platelet dysfunction. Other
studies have indicated that platelet cAMP is reduced in
Cd73-deficient mice, suggesting that plasma adenosine
levels regulate basal platelet cAMP, and that decreases in
circulating adenosine in Cd73-deficient animals contribute
to such changes. Additional studies of platelet function and
clotting will be necessary to define the contribution of
CD73 to these pathways.
Therapeutic potential for CD73
The design and implementation of adenosine receptor
agonists and antagonists is currently an area of intense
investigation [80, 81]. While drugs targeting adenosine
receptors hold great promise in a variety of diseases,
specificity and pharmacodynamics have been significant
challenges [2]. As an alternative to modulating adenosine
receptor signaling with agonists or antagonists, it may be
possible to manipulate extracellular adenosine concentra-
tions. Unfortunately, under many circumstances the source
of endogenous adenosine is unclear. However, in cases
where the prominent pathway involves extracellular me-
tabolism of ATP and/or AMP, it may be possible to
regulate these metabolic steps.
One strategy may be to enhance the extracellular
adenosine formation. Some work has been done in this
regard. For example, methotrexate and sulfasalazine have
been shown to increase extracellular adenosine [82]. Such
increases in adenosine were shown to involve a CD73-
mediated step both in vitro and in vivo. Alternatively,
targeted use of soluble nucleotidases could provide an
additional mechanism. Administration of 50-nucleotidase
has been shown to be beneficial in a number of
experimental scenarios. For example, soluble 50-nucleotid-
ase promotes vascular barrier function and decreases
neutrophil accumulation in inflammatory models [7, 12].
A significant limitation for this line of work has been the
identification of a reliable source of purified protein.
Ironically, one of the major sources of 50-nucleotidase
may be snake venoms, particularly those from rattlesnakes
(genera Crotalus and others) [83]. It is thought that snakes
utilize purines as an effective, multifunctional means of
envenomation [84].
CD73 directed therapies have not been well-developed.
In our own experience, we have documented use of the
CD73 inhibitor ab-methylene ADP (APCP) in various
murine models [7, 12, 18]. APCP is well tolerated,
biologically available through the oral route, and non-toxic
in mice up to 60 mg/kg/day. Anecdotally, we have noticed
that APCP treatment of mice appears to promote subtle
increases in aggressive behavior and anxiety (unpublished
observation). It is possible that this behavior is related to
previous findings of increased aggression in adenosine A1r-
and A2Ar-deficient mice [85, 86], and may suggest that
APCP is biologically available across the central nervous
system. While many studies have suggested that adenosine
is beneficial for most host responses, there may be
examples where inhibition of adenosine generation (e.g.,
by inhibition of CD73) is warranted. As alluded to above,
during enteric pathogen infection, adenosine may promote
water transport across intestinal epithelia and the symp-
toms of secretory diarrhea. For these purposes, CD73
inhibitors such as APCP could prove effective as anti-
diarrheals. In this same context, it is possible that
pulmonary edema related to infectious pneumonia or
inflammation may benefit from the use of CD73 inhibitors.
Studies directed at defining these principles are currently
underway.
Given the established association between angiogenesis
and adenosine A2 receptor activation, the controlled
regulation of CD73 activity could influence angiogenesis.
It is possible, for example, that systemic administration
Physiologic roles for CD73 357and/or targeting of CD73 inhibitors could prove beneficial
for inhibition of tumor angiogenesis, currently an area of
keen interest in cancer research. This is particularly
compelling given the known association between hypoxia
and the tumor microenvironment [87], wherein hypoxia
and HIF-1 activation are potent transcriptional stimuli for
CD73 expression [18] (also see above). Under such
circumstances, it is reasonable that many tumors might
over-express CD73. Thus, inhibition of adenosine produc-
tion by CD73 could be a therapeutic target for the
prevention of tumor angiogenesis and metastasis. Experi-
ments to test this hypothesis are in progress.
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